
Luxury Products and Fashion
The world of fashion raises legal issues that can be as intriguing as the designs that glide down runways. Our lawyers are ready with integrated, detailed, and creative solutions to address the many challenges faced by luxury and fashion brands around the world.
From intellectual property matters to superannuation, we handle a myriad of issues affecting these businesses throughout the life cycle of their products. As a founding partner of the Luxury Law Alliance and the Luxury Law Summit, we are on the forefront as thought leaders. We have unique partnerships with the Camera Nazionale Della Moda Italiana, The Fédération française de la Couture, du Prêt à Porter des Couturiers et des Créateurs de Mode in France, and The Melbourne Fashion Festival in Australia. These important connections place our firm at the forefront of industry events across the globe.
Our experienced luxury products and fashion lawyers provide counsel on a broad spectrum of matters, including:
- Artificial intelligence
- Blockchain
- Commercial agreements, collaboration, and licensing
- Distribution strategies and antitrust policies
- Insurance
- Risk management
- Intellectual property
- International trade
- Logistics transactions
- Real estate
- Regulatory and compliance
- Restructuring, mergers and acquisitions, capital markets, and securities
- Technology and data protection
Thought Leadership
On 22 December 2020, the U.S. Securities and Exchange Commission (SEC) adopted amendments (the final rule) to Rule 206(4)-1 under the Investment Advisers Act of 1940 (the Advisers Act) to modernize the regulation of investment adviser advertising and solicitation practices.
On 7 January 2021, the U.S. Equal Employment Opportunity Commission (EEOC) proposed two new rules designed to clarify the scope of incentives that employers may offer employees as part of a wellness program without violating the Americans with Disabilities Act (ADA) or Genetic Information Nondiscrimination Act (GINA).
Following earlier announcements as to the efficacy of vaccine trials by pharmaceutical companies Pfizer, Inc. (Pfizer) and Moderna, Inc. on November 20, 2020, Pfizer and BioNTech submitted applications for emergency use authorization to the U.S. Food and Drug Administration (FDA) for their COVID-19 vaccinations.
On Wednesday, 6 January 2021, the U.S. Small Business Administration (SBA) released new guidance on the existing Paycheck Protection Program (PPP) under Sections 1102 and 1106 of the Coronavirus Aid, Relief, and Economic Security Act and on the SBA’s new “Paycheck Protection Program Second Draw Loans."